Our study population included both MAB and HAB and, as previously demonstrated by our group, the rs6971 single-nucleotide polymorphism of the TSPO gene, other than affecting [11C]PBR28 and other second-generation TSPO tracers binding, does not affect any others of the clinical, neuropsychological, and biomarker characteristics of an AD or MCI population; thus, the results of the genetic subgroups can be applied to the entire MCI population.50 This evidence concerns the gene TSPO and Alzheimer disease.